MetaCap

Moleculin Biotech (MBRX) vs Palatin Technologies (PTN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Moleculin Biotech is the larger company by market cap ($8.2 million vs $8.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBRX+1663.50%PTN-51.89%
+2114%+980%-155%
Oct 7, 20261 yearNov 20, 2026
MBRX+1651.13%PTN-46.74%
+1964%+911%-142%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBRX versus PTN key metrics
MetricMBRXPTN
Share price$7.74$4.58
Market cap$8.22M$8.16M
1-day change-2.40%-7.10%
YTD return—-70.22%
1-year return—-79.93%
5-year return—-99.35%
P/E ratio (TTM)0.04—
EPS (TTM)$179.60$-2.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$8.83M
Net income (latest FY)$-33.56M$-8.38M
Operating margin—-98.17%
Net margin—-94.88%
52-week high$202.50$31.00
52-week low$3.22$4.51
Distance from 52-week high-96.18%-85.23%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+55.04%+1068.12%
Average volume44.66K71.93K
Shares outstanding1.06M1.78M
Employees1725
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

MBRX vs PTN FAQ

Which is bigger, Moleculin Biotech or Palatin Technologies?

Moleculin Biotech (MBRX) is larger, with a market capitalization of $8.22M compared with $8.16M for Palatin Technologies (PTN).

Are Moleculin Biotech and Palatin Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons